文献速递浆细胞疾病

新型PIM2激酶抑制剂对多发性骨髓瘤具有显著抗肿瘤疗效

Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
PubMed 文献 · Leukemia · 2016-12-23

研究证实PIM2在多发性骨髓瘤(MM)患者中过表达,尤其在高危MF亚群中;发现新型PIM2选择性非ATP竞争性抑制剂JP11646,其抑制MM增殖和活力的效果比ATP竞争性PIM抑制剂强4至760倍,机制涉及下调PIM2 mRNA和蛋白表达;在异种骨髓瘤小鼠模型中,JP11646显著减少肿瘤负荷并延长中位生存期。

要点

  • PIM2在MM患者中过表达,尤其在高危MF亚群中。
  • JP11646抑制MM增殖和活力的效果比ATP竞争性PIM抑制剂强4至760倍。
  • JP11646在异种骨髓瘤小鼠模型中显著减少肿瘤负荷并延长中位生存期。

核心结论

  • 研究提示存在先前未被认识的反馈环路,即PIM2激酶活性调控恶性细胞中PIM2基因表达,JP11646代表一类新型PIM2抑制剂可阻断该反馈。

研究设计与样本

  • 研究确认PIM2在MM患者中过表达,并识别出新型PIM2选择性非ATP竞争性抑制剂JP11646,在异种骨髓瘤小鼠模型中进行治疗评估。

主要发现

  • PIM2在MM患者中过表达,并在MM组内的高危MF亚群(原癌基因MAF/MAFB激活)中过表达。
  • JP11646对MM增殖和活力的抑制比ATP竞争性PIM抑制剂强4至760倍。
  • JP11646的增强疗效不仅源于抑制PIM2激酶活性,还涉及特异性下调PIM2 mRNA和蛋白表达的新机制,而ATP竞争性抑制剂未见此作用。
  • 在异种骨髓瘤小鼠模型中,JP11646治疗显著减少肿瘤负荷并延长中位生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The PIM kinase family (PIM1, 2 and 3) have a central role in integrating growth and survival signals, and are expressed in a wide range of solid and hematological malignancies. We now confirm that PIM2 is overexpressed in multiple myeloma (MM) patients, and within MM group it is overexpressed in the high-risk MF subset (activation of proto-oncogenes MAF/MAFB). This is consistent with our finding of PIM2's role in key signaling pathways (IL-6, CD28 activation) that confer chemotherapy resistance in MM cells. These studies have identified a novel PIM2-selective non-ATP competitive inhibitor (JP11646) that has a 4 to 760-fold greater suppression of MM proliferation and viability than ATP-competitive PIM inhibitors. This increased efficacy is due not only to the inhibition of PIM2 kinase activity, but also to a novel mechanism involving specific downregulation of PIM2 mRNA and protein expression not seen with the ATP competitive inhibitors. Treatment with JP11646 in xenogeneic myeloma murine models demonstrated significant reduction in tumor burden and increased median survival. Altogether our findings suggest the existence of previously unrecognized feedback loop(s) where PIM2 kinase activity regulates PIM2 gene expression in malignant cells, and that JP11646 represents a novel class of PIM2 inhibitors that interdicts this feedback.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Nair JR, Caserta J, Belko K, et al. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia. 2016. PMID: 28008178. doi:10.1038/leu.2016.379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。